Abstract: The present disclosure relates to a belted transmission system configured to couple with load motors to provide a load to a device under test. The belted transmission system comprises a spindle coupled with the device under test. The spindle comprises various components configured to facilitate high operational speeds and increased power relative to prior art systems. For example, the spindle comprises a shaft having a larger diameter at one end compared to the other, one or more bearings configured to facilitate rotation of the shaft, and a sprocket coupled to the shaft configured to receive belts coupled to load motors such that the shaft is driven by the one or more belts to turn the spindle and load the device under test. The belted transmission includes a housing configured to enclose the belts and at least a portion of the spindle.

Abstract: The present disclosure relates to a belted transmission system configured to couple with load motors to provide a load to a device under test. The belted transmission system comprises a spindle coupled with the device under test. The spindle comprises various components configured to facilitate high operational speeds and increased power relative to prior art systems. For example, the spindle comprises a shaft having a larger diameter at one end compared to the other, one or more bearings configured to facilitate rotation of the shaft, and a sprocket coupled to the shaft configured to receive belts coupled to load motors such that the shaft is driven by the one or more belts to turn the spindle and load the device under test. The belted transmission includes a housing configured to enclose the belts and at least a portion of the spindle.

Abstract: Compounds of formula (I) and salts thereof: wherein R1, R2, R3, a, X1, X2, X3, X4, and X5 are as defined hereinbefore. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain containing proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.

Abstract: Compounds of formula (I) and salts thereof: wherein R1, R2, R3 and a are as defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain containing proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.

Abstract: A pharmaceutical composition for the treatment of migraine or overindulgence comprising a therapeutically effective amount of racemic ibuprofen or a pharmaceutically acceptable salt or an enantiomer or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of prochlorperazine or a pharmaceutically acceptable salt thereof.